Injectable Drug Delivery Resources

  1. Single Source Partner: Seamless Approach To Deliver World-Class Treatment 5/5/2022

    Growing demand for high-value, complex therapies requires the right containment and delivery systems: solutions that offer superior quality and patient comfort while meeting stringent regulatory requirements. 

  2. Characterizing The E&L Profile Of Stoppers For Drug Stability 6/11/2024

    The significance of E&L testing lies in its ability to identify potential risks associated with the use of containers and packaging materials in the pharmaceutical industry.

  3. A Risk-Based Approach To Injectable Combination Product Development 3/14/2023

    Examine how to establish a holistic approach to drug-device combination product (DDCP) development and how to assess and manage risk throughout the development and approval process.

  4. De-Risking Visible Particles Through Component Selection

    Explore a summary of the FDA’s recent draft guidance “Inspection of Injectable Products for Visible Particulates” and how it applies to components.

  5. Experimental And Theoretical Evaluation Of Vial Container Closure System Components 10/18/2022

    Review the comparison of two container closure systems which differ by stopper hardness using comprehensive stack-up calculations performed by West’s DeltaCube™ Modeling Platform.

  6. 5 Ways Pre-Filled Syringes Contribute To Better Patient Outcomes 5/23/2025

    In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

  7. Selecting An Alternative Coating Technology To Silicone Oil For Prefillable Syringes 5/5/2022

    The challenges of silicone-oil lubrication and the growing trend for more viscous, protein-based drugs are now leading pharma and biotech companies to investigate alternative solutions.

  8. A Smooth Transition To USP <382> With Established Expertise 3/16/2026

    A new regulatory chapter requires holistic, real‑world testing of injectable systems, mandating full‑system validation with actual drug products and prioritizing patient‑centric performance and safety.

  9. How Lipid Nanoparticles Overcome Solubility Challenges 3/7/2023

    More than 80% of NCEs are poorly soluble compounds. Overcoming this challenge using lipid nanoparticles is essential to move your drug product through the pipeline and into the market.

  10. Engineered for Injectable Drug Delivery Excellence: The Bridgeton Site 1/23/2026

    Purpose‑built for modern injectable drug delivery, we integrate advanced aseptic filling, in‑line quality, and capacity to support complex products.